• Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Corporation
Lifestyle

Raphas Co., Ltd. Collaborates with Hosokawa Micron to Develop ‘PLGA Nano-Microneedles’... Targets Next-Generation DDS Market

Raphas ( Raphas Co., Ltd.(214260)), a company specializing in microneedle patches, has partnered with Japan’s leading global advanced materials company, Hosokawa Micron, to begin a full-scale push int…
  • 2026-07-01 09:47:32
  • YU JIN-HEE
Lifestyle

Celltrion’s ‘Truxima’ Becomes First Rituximab Biosimilar in the U.S. to Gain Interchangeability Status

(Photo courtesy of Celltrion) Celltrion(068270)announced on the 1st that its blood cancer treatment “Truxima” (active ingredient: rituximab) has obtained interchangeability status from the U.S. Fo…
  • 2026-07-01 09:04:02
  • SONG YOUNG-DOO
Lifestyle

Ensol Bio Makes Another Attempt at Relisting on KOSDAQ... ‘Green Light’ as It Demonstrates Profitability and Technological Capabilities

Ensol Biosciences (hereinafter “Ensol Bio”), a company specializing in the development of innovative new drugs, is moving full steam ahead with its transfer listing to KOSDAQ. Unlike its previous atte…
  • 2026-07-01 09:01:03
  • YU JIN-HEE
Lifestyle

HITEJINRO Launches Limited-Edition Jinro Light with Reduced Calories

HITEJINRO(000080)is launching a limited-edition version of its new low-calorie soju product, Jinro Light, targeting the summer season. HITEJINRO announced on the 1st that it will begin rolling …
  • 2026-07-01 08:53:12
  • SIN SOO-JUNG
Lifestyle

New Approach to Treating Fishy Odor Syndrome… Yoon Sang-seon, CEO of Biomi: “Directly Breaking Down TMA in the Gut”

“Telling patients with fishy odor syndrome not to eat eggs or meat is not a realistic treatment. People have to eat to survive.”These were the first words heard during an exclusive interview conducted…
  • 2026-07-01 08:41:01
  • KIM JI-WAN
Lifestyle

Why ECM Skinbooster Is Maintaining a ‘Two-Track’ Approach to Distribution and Sales

Amid an explosive surge in demand for extracellular matrix (ECM)-based products in the skin booster market, HANS BIOMED CORPORATION(042520)and L&C BIO(290650)—which currently dominate the domestic mar…
  • 2026-07-01 08:31:02
  • Kim Jinsoo
Lifestyle

CU Selects Girl Group Lisenne as Brand Models… “Targeting the K-pop Fandom”

CU, a convenience store chain operated by BGF Retail(282330), has selected the rising girl group RESCENE as its new brand model. This marks the first time a convenience store chain has chosen a K-pop …
  • 2026-07-01 08:26:45
  • Kim Ji-woo
Lifestyle

[Bio USA] Jeong In-ki, CEO of GID Partners and “Key Player in the Hanmi Big Deal”: “Big Pharma Was the First to Discover a Cell Therapy for Parkinson’s Disease”

“To be honest, I was skeptical at first. I wondered if a treatment that involves directly implanting cells into the brain of each individual patient was even realistically possible. But after reviewin…
  • 2026-07-01 08:22:02
  • SONG YOUNG-DOO
Lifestyle

Vaxcell-Bio Therapeutics Set to Benefit Most from Revisions to the Advanced Biotechnology Act… O-Rim Rises on Expectations of a 'Big Deal' in China [Bio Spotlight]

On the 29th, the domestic pharmaceutical and life sciences sectors surged in tandem. The pharmaceutical sector index rose 9.52% compared to the previous trading day, with 143 out of 160 listed stocks …
  • 2026-07-01 08:01:05
  • KIM JI-WAN
Lifestyle

SAMSUNG PHARMACEUTICAL Submits Phase 3 Clinical Trial Protocol for Progressive Supranuclear Palsy in South Korea

SAMSUNG PHARMACEUTICAL(001360)announced on the 30th that it has submitted an application for a Phase 3 clinical trial in Korea for “GV1001,” a treatment for progressive supranuclear palsy (PSP), to th…
  • 2026-06-30 21:40:03
  • KIM JI-WAN
prev 41 42 43 44 45 46 47 48 49 50 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea
English